CTOs on the Move

Fluence Analytics

www.fluenceanalytics.com

 
Fluence Analytics is a leader in continuous analytics and process control solutions for the polymer and biopharmaceutical industries. The company offers two product lines, ACOMP and ARGEN. ACOMP is a polymer smart manufacturing system that generates ne...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Avatar International

Avatar International is a Lake Mary, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vet XPS

Vet XPS is a company that provides veterinary medical services and products. They are based in Charlotte, North Carolina and follow FDA guidelines.

AIDS Services

AIDS Services is a Denton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northeast Dental

Northeast Dental is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.